Clinical resistance to TKI therapy in CML is a significant problem and is classified as acquired resistance (increasing BCR-ABL1 transcript levels following a substantial decrease) or primary resistance (lack of an adequate initial response). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.